SEC Form 4 · accession 0000899243-18-031128
CORCEPT THERAPEUTICS INC · CORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Joseph K Belanoff
Officer — Chief Executive Officer · Director
Period of report
Dec 12, 2018
Accepted (ET)
Dec 14, 2018 · 7:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001088856
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 12, 2018 | M | 217,115 | $1.19 | A | 2,381,310 | D | |
| Common StockF1 | Dec 12, 2018 | S | 217,115 | $19.0061 | D | 2,164,195 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.19 | Dec 12, 2018 | M | 217,115 | D | — | Feb 7, 2028 | Common Stock | 217,115 | 282,885 | D |
Explanation of responses
- F1Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $18.75 to $19.48 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
- F2Fully exercisable.